Inspire Corporate Bond ETF (IBD)
ARCA ARCA Primary 
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
The Inspire Corporate Bond ETF (IBD) was launched on 07/10/2017, and is a smart beta exchange traded fund designed to offer broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
Designed to provide broad exposure to the Investment Grade Corporate Bond ETFs category of the market, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund launched on 07/10/2017.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.
Gold Stocks Steal The Luster In IBD Growth List; These Stocks Stand Out
Gold stock Agnico Eagle Mines has passed a buy point and outperformed the S&P 500. Other gold stocks have entered the IBD 50.
GE, IBD's Stock Of The Day, Doubles Investments In U.S. Factories
GE Aerospace doubling investments in U.S. factories with commercial and military jet-engine deliveries set to grow. The post GE, IBD's Stock Of The Day, Doubles Investments In U.S. Factories appeared first on Investor's Business Daily.
Spyre Therapeutics: Targeting The Future Of IBD Treatment
Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better efficacy and long-term disease control in ulcerative colitis.
Nvidia Earnings Preview: Blackwell, DeepSeek And Big Expectations | Earnings Cheat Sheet | IBD
IBD's Alissa Coram and Ed Carson preview key upcoming earnings reports from Nvidia, Axon and Cava. Check out our daily newsletter!
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Piper Sandler analyst David Amsellem reiterated the Overweight rating on Teva Pharmaceutical Industries Limited TEVA with a price forecast of $30.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
